Browse
Submit Data
Databases
API
Help

Dataset Information

0 Views

0 Connections

0 Citations

0 Reanalyses

0 Downloads

Omics score: 0

ABSTRACT: ChIP-seq based on HEI-OC1-Gfi1 samples treated with cisplatin

PROVIDER: PRJNA1187857 | ENA |

REPOSITORIES: ENA

ACCESS DATA

Json Xml

Dataset's files

Source:

			Action	DRS
	SRR31393069_1.fastq.gz	Fastqsanger.gz
	SRR31393069_2.fastq.gz	Fastqsanger.gz
	SRR31393070_1.fastq.gz	Fastqsanger.gz
	SRR31393070_2.fastq.gz	Fastqsanger.gz
	SRR31393071_1.fastq.gz	Fastqsanger.gz

Items per page:

1 - 5 of 8

Similar Datasets

Transcriptomic in silico screens identify niclosamide for protection against cisplatin- and noise-induced hearing loss in zebrafish and mice through Nrf2 activation

Project description:We report the RNA expression of the House Ear Institute-Organ of Corti (HEI-OC1) cells with and without cisplatin exposure to identify differencialyy expressed genes. The results of RNA-seq analysis showed 2732 downregulated, and 1639 upregulated genes above 1-fold change in cisplatin threated cells compared to non-treated controls.

2021-07-16 | GSE180141 | GEO

Integration of transcriptomics and proteomics uncovers novel targets underlying the protective effects of Nrf2 knockout in HEI-OC1 cells

Project description:Cisplatin, a utilized anticancer drug in clinical practice, induces sensorineural hearing loss (SNHL) in patients. However, the precise mechanism underlying cisplatin-associated ototoxicity remains unknown. HEI-OC1 cells are immortalized cells derived from the organs of Corti mice and nuclear factor erythroid 2-related factor 2 （Nrf2） knockout (KO) significantly enhances cisplatin resistance in these cells. The exploration of transcriptomic data from Nrf2 KO has significant implications for the identification of novel targets to enhance HEI-OC1 cisplatin resistance in Nrf2 KO and for understanding the biological characteristics associated with SNHL. The RNA-seq analysis revealed a significant enrichment of differentially expressed genes (DEGs) in the Nrf2 KO model within key signaling pathways, including the PI3K-Akt, MAPK, as well as Glutathione metabolism signaling pathways. Notably, expression levels of 17 specific genes were confirmed by RT-qPCR (Real-time Quantitative-PCR). The biomarkers identified in this study may be key to understanding the biological mechanism by which Nrf2 KO strongly increases HEI-OC1 cisplatin resistance, and by targeting the PI3K-Akt, MAPK, Glutathione metabolism signaling pathways provide new ideas for the prevention and treatment of cisplatin-induced SNHL.

2024-09-01 | GSE268900 | GEO

Phosphoproteomics on cisplatin or LPS treated on HEI OC1 cells

Project description:HEI-OC1 cells were treated with cisplatin, LPS or PB and lysed with 8 M guanidine hydrochloride. Soluble proteins were digested to peptides with trypsin/LysC mix and desalted. Phosphopeptides were enriched using MagReSyn Ti-IMAC HP beads automtaed by KingFIsher Duo Prime.

2024-12-11 | MSV000096638 | MassIVE

Project description:HEI-OC1 cells sequencing

| PRJNA1080024 | ENA

Clinical and molecular characterization of a novel LMX1A frameshift mutation near the C-terminus lead to familial non-syndromic sensorineural hearing loss

Project description:Next Generation Sequencing Facilitates Quantitative Analysis of HEI-OC1 cells transduced with vector control, LMX1A WT or c.915dup variant.

2025-04-11 | GSE200599 | GEO

Effect of Gfi1 36N variant on genome-wide H3K9 Acetylation patterns

Project description:ChIP-Seq Analysis of H3K9Ac in pairs of mouse and human samples carrying either the Gfi136S or the GFi136N variants. The objective of the study was to identify the changes in H3K9 acetylation at gene promoters that occur in samples expressing the 36N variant of the Gfi1 gene. 3 pairs of bone-marrow AML samples were obtained from mice where 1 mouse in each pair was homozygous for Gfi136S and 1 heterozygous for Gfi136N, or homozygous for 36N in one case. 2 pairs of AML samples were obtained from human patients were 1 patient was homozygous for Gfi1 36S and one was heterozygous for Gfi1 36N. H3 and H3K9Ac ChIP-Seq was carried out on each sample.

2016-08-01 | E-GEOD-71254 | biostudies-arrayexpress

Uracil DNA glycosylase (UNG) loss enhances DNA double strand break formation in human cancer cells exposed to pemetrexed

Project description:To test the effects of uracil DNA glycosylase (UNG) loss on the formation of double strand breaks (DSBs) by the anti-cancer agent pemetrexed, we performed ChIP-seq for serine 139-phosphorylated H2AX (gammaH2AX), a marker of DSBs, in human cells wild-type or deficient for UNG in combination with pemetrexed treatment. UNG deficiency results in an increase in DSBs upon pemetrexed treatment, and we found that pemetrexed treatment induces DSBs at different genomic locations in UNG wild-type and knockout cells. Similar results were observed upon cisplatin treatment of UNG wild-type and knockout cells, and the genomic locations of DSBs were distinct between pemetrexed-treated and cisplatin-treated samples. Taken together, our results suggst differential mechanisms for DSB formation in UNG-competent and UNG-deficient cells. The genomic distribution of gammaH2AX in UNG WT and KO cells treated with pemetrexed or cisplatin was determined by ChIP-seq

2013-10-28 | E-GEOD-50692 | biostudies-arrayexpress

Effect of Gfi1 36N variant on genome-wide H3K9 Acetylation patterns

2016-08-01 | GSE71254 | GEO

Identification of GFI1 target genes in human lung adenocarcinoma cell line A549 [ChIP-seq]

Project description:To investigate the genes regulated by the transcription factor GFI1 in lung cancer cells, we overexpressed GFI1-Flag in A549 cells and performed ChIP-Seq with anti-Flag affinity gel.

2022-09-14 | GSE164984 | GEO

Identify genome-wide binding sites of GFI1 in NB4 cells

Project description:Abarrent transcriptional regulation is one of hallmarks of leukemia. GFI1 is a transcriptional regulator with context-dependent roles in hematopoiesis and leukemogenesis. Reduced or loss of GFI1 expression has been reported in myeloid malignancies, while high GFI1 expression has been observed in AML1-ETO-positive acute myeloid leukemia (AML) and acute lymphoid leukemia, but without clear roles defined for GFI1 in APL pathogenesis. We here performed ChIP-seq analysis using antibodies against GFI1 and identified genome-wide binding site of GFI1 in NB4 cells.

2020-08-26 | GSE154269 | GEO

OmicsDI is part of the ELIXIR infrastructure

OmicsDI is an Elixir interoperability service. Learn more ›

Tweets

OmicsDI Databases

PRIDE
PeptideAtlas
MassIVE
JPOST Repository
Physiome Model Repository

EGA
EVA
ENA
LINCS
PAXDB
Cell Collective

MetaboLights
Metabolomics Workbench
MetabolomeExpress
GNPS
BioModels
FAIRDOMHub

ArrayExpress
dbGaP
ExpressionAtlas
GEO
NODE

Information

Databases
Help
API
Contact us
Code on GitHub
Terms of use
Submit Data